Apr 2020 - Niclosamide inhibits uveal melanoma in tests

We have known about this drug for a while as it is a favourite in the metabolic treatment of cancers. There is a good listing of its potential in various cancer settings  HERE. In 2017 lab testing was carried out to see the relevance of this antihelminthic drug niclosamide which showed that it effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. You can rean the full report HERE.